Nafoxidine

Nafoxidine
Clinical data
ATC code none
Identifiers
CAS Number 1845-11-0
PubChem (CID) 4416
IUPHAR/BPS 4263
ChemSpider 4263
UNII 4RIY10WM82 YesY
ChEMBL CHEMBL28211
ECHA InfoCard 100.222.756
Chemical and physical data
Formula C29H31NO2
Molar mass 425.562 g/mol
3D model (Jmol) Interactive image

Nafoxidine (INN) (developmental code names U-11,000A, NSC-70735), or nafoxidine hydrochloride (USAN), is a non-steroidal selective estrogen receptor modulator (SERM) or partial antiestrogen of the triphenylethylene group that was developed for the treatment of advanced breast cancer by Upjohn in the 1970s but was never marketed.[1][2][3] It was developed at around the same time as tamoxifen and clomifene, which are also triphenylethylene derivatives.[2] The drug was originally synthesized by the fertility control program at Upjohn as a postcoital contraceptive, but was subsequently repurposed for the treatment of breast cancer.[4] It showed clinical effectiveness in breast cancer,[5] but development was terminated due to the incidence of severe photophobia.[4][6]

References

  1. ↑ J. Elks (14 November 2014). The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Springer. pp. 848–. ISBN 978-1-4757-2085-3.
  2. 1 2 JORDAN V. CRAIG; B.J.A. Furr (5 February 2010). Hormone Therapy in Breast and Prostate Cancer. Springer Science & Business Media. pp. 95–96. ISBN 978-1-59259-152-7.
  3. ↑ Georg F. Weber (22 July 2015). Molecular Therapies of Cancer. Springer. pp. 361–. ISBN 978-3-319-13278-5.
  4. 1 2 Hormones and Breast Cancer. Elsevier. 25 June 2013. pp. 32–. ISBN 978-0-12-416676-9.
  5. ↑ Steinbaum, Fred L.; de Jager, Robert L.; Krakoff, Irwin H. (1978). "Clinical trial of nafoxidine in advanced breast cancer". Medical and Pediatric Oncology. 4 (2): 123–126. doi:10.1002/mpo.2950040207. ISSN 0098-1532.
  6. ↑ Aurel Lupulescu (24 October 1990). Hormones and Vitamins in Cancer Treatment. CRC Press. pp. 95–. ISBN 978-0-8493-5973-6.


This article is issued from Wikipedia - version of the 10/4/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.